Evidence map›Paper›PMID 17971525›Full record

Trial reportJournal of the National Cancer Institute2007

Proliferative changes in the bronchial epithelium of former smokers treated with retinoids.

Walter N Hittelman, Diane D Liu, Jonathan M Kurie, Reuben Lotan, Jin Soo Lee, Fadlo Khuri, Heladio Ibarguen, Rodolfo C Morice, Garrett Walsh, Jack A Roth and 5 more

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the National Cancer Institute, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Oral iloprost improves endobronchial dysplasia in former smokers.Cancer prevention research (Philadelphia, Pa.) · 2011
    Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Walter N HittelmanDepartment of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Box 19, 1515 Holcombe Blvd, Houston, TX 77030, USA. whittelm@mdanderson.org
Diane D Liu
Jonathan M Kurie
Reuben Lotan
Jin Soo Lee
Fadlo Khuri
Heladio Ibarguen
Rodolfo C Morice
Garrett Walsh
Jack A Roth
John Minna
Jae Y Ro
Anita Broxson
Waun Ki Hong
J Jack Lee
Southwestern Medical Center · USThe University of Texas Southwestern Medical Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4M
MECHANISMS OF LUNG CANCER PREVENTIONU19CA068437 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI HONG, WAUN KI · 1995 to 1999
–
NCI NIH HHS P30 CA016672NCI NIH HHS P30CA16672NCI NIH HHS P50 CA070907NCI NIH HHS P50CA70907NCI NIH HHS U19 CA068437NCI NIH HHS U19CA68437
6 · The paper itself

Abstract

backgroundRetinoids have shown antiproliferative and chemopreventive activity. We analyzed data from a randomized, placebo-controlled chemoprevention trial to determine whether a 3-month treatment with either 9-cis-retinoic acid (RA) or 13-cis-RA and alpha-tocopherol reduced Ki-67, a proliferation biomarker, in the bronchial epithelium.

methodsFormer smokers (n = 225) were randomly assigned to receive 3 months of daily oral 9-cis-RA (100 mg), 13-cis-RA (1 mg/kg) and alpha-tocopherol (1200 IU), or placebo. Bronchoscopic biopsy specimens obtained before and after treatment were immunohistochemically assessed for changes in the Ki-67 proliferative index (i.e., percentage of cells with Ki-67-positive nuclear staining) in the basal and parabasal layers of the bronchial epithelium. Per-subject and per-biopsy site analyses were conducted. Multicovariable analyses, including a mixed-effects model and a generalized estimating equations model, were used to investigate the treatment effect (Ki-67 labeling index and percentage of bronchial epithelial biopsy sites with a Ki-67 index > or = 5%) with adjustment for multiple covariates, such as smoking history and metaplasia. Coefficient estimates and 95% confidence intervals (CIs) were obtained from the models. All statistical tests were two-sided.

resultsIn per-subject analyses, Ki-67 labeling in the basal layer was not changed by any treatment; the percentage of subjects with a high Ki-67 labeling in the parabasal layer dropped statistically significantly after treatment with 13-cis-RA and alpha-tocopherol treatment (P = .04) compared with placebo, but the drop was not statistically significant after 9-cis-RA treatment (P = .17). A similar effect was observed in the parabasal layer in a per-site analysis; the percentage of sites with high Ki-67 labeling dropped statistically significantly after 9-cis-RA treatment (coefficient estimate = -0.72, 95% CI = -1.24 to -0.20; P = .007) compared with placebo, and after 13-cis-RA and alpha-tocopherol treatment (coefficient estimate = -0.66, 95% CI = -1.15 to -0.17; P = .008).

conclusionsIn per-subject analyses, treatment with 13-cis-RA and alpha-tocopherol, compared with placebo, was statistically significantly associated with reduced bronchial epithelial cell proliferation; treatment with 9-cis-RA was not. In per-site analyses, statistically significant associations were obtained with both treatments.

Indexed as

SmokingSmoking CessationAdultAgedAlitretinoinalpha-TocopherolAnticarcinogenic AgentsAntineoplastic AgentsBiomarkersBronchiCell ProliferationDouble-Blind MethodFemaleHumansImmunohistochemistryIsotretinoinAlitretinoinalpha-TocopherolAnticarcinogenic AgentsAntineoplastic AgentsBiomarkersIsotretinoinKi-67 AntigenTretinoin

Identifiers

PMID17971525
PMCPMC3441140
OpenAlexW2118931738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.